Metraipolis › archive › dc_dc2be31a9937
Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure — Europe PMC PMID:31790515
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/31790515
- DOI
- 10.1371/journal.ppat.1008157
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-09T23:57:50.166Z
- SHA-256 of the archived text
3353d23256fbc2b83560bb6e6f91a74e18e7710959fa910530ec0eaf3e1e325e- Stable URL of this page
https://metraipolis.com/documento/dc_dc2be31a9937
How to cite
Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure — Europe PMC PMID:31790515 — Europe PMC (en), https://europepmc.org/article/MED/31790515 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_dc2be31a9937 (Metraipolis archive dc_dc2be31a9937, sha256 3353d23256fbc2b83560bb6e6f91a74e18e7710959fa910530ec0eaf3e1e325e)
BibTeX
@misc{dcdc2be31a9937,
title = {Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure — Europe PMC PMID:31790515},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/31790515},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_dc2be31a9937; sha256 3353d23256fbc2b83560bb6e6f91a74e18e7710959fa910530ec0eaf3e1e325e},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/31790515. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
There are no FDA licensed vaccines or therapeutics for Venezuelan equine encephalitis virus (VEEV) which causes a debilitating acute febrile illness in humans that can progress to encephalitis. Previous studies demonstrated that murine and macaque monoclonal antibodies (mAbs) provide prophylactic and therapeutic efficacy against VEEV peripheral and aerosol challenge in mice. Additionally, humanized versions of two neutralizing mAbs specific for the E2 glycoprotein, 1A3B-7 and 1A4A-1, administered singly protected mice against aerosolized VEEV. However, no studies have demonstrated protection in nonhuman primate (NHP) models of VEEV infection. Here, we evaluated a chimeric antibody 1A3B-7 (c1A3B-7) containing mouse variable regions on a human IgG framework and a humanized antibody 1A4A-1 containing a serum half-life extension modification (Hu-1A4A-1-YTE) for their post-exposure efficacy in NHPs exposed to aerosolized VEEV. Approximately 24 hours after exposure, NHPs were administered a single bolus intravenous mAb. Control NHPs had typical biomarkers of VEEV infection including measurable viremia, fever, and lymphopenia. In contrast, c1A3B-7 treated NHPs had significant reductions in viremia and lymphopenia and on average approximately 50% reduction in fever. Although not statistically significant, Hu-1A4A-1-YTE administration did result in reductions in viremia and fever duration. Delay of treatment with c1A3B-7 to 48 hours post-exposure still provided NHPs protection from severe VEE disease through reductions in viremia and fever. These results demonstrate that post-exposure administration of c1A3B-7 protected macaques from development of severe VEE disease even when administered 48 hours following aerosol exposure and describe the first evaluations of VEEV-specific mAbs for post-exposure prophylactic use in NHPs. Viral mutations were identified in one NHP after c1A3B-7 treatment administered 24 hrs after virus exposure. This suggests that a cocktail-based therapy, or an alternative mAb against an epitope that cannot mutate without resulting in loss of viral fitness may be necessary for a highly effective therapeutic. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS pathogens, 2019 (prima pubblicazione 2019-12-02). Identificativi: PMID 31790515 · PMCID PMC6907853 · DOI 10.1371/journal.ppat.1008157. Pagina: https://europepmc.org/article/MED/31790515 — https://doi.org/10.1371/journal.ppat.1008157. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-09T23:54:52.635Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.